Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. - Wikidata - awgldk - TriplyDB

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

http://www.wikidata.org/entity/Q37835572

about

Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies Three-drug versus two-drug induction therapy regimens for patients with transplant-eligible multiple myeloma Many multiple myelomas: making more of the molecular mayhem Targeted treatments for multiple myeloma: specific role of carfilzomib International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma Advances in understanding prognosis in myeloma.Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.Durable remission with salvage second autotransplants in patients with multiple myeloma.Implications of heterogeneity in multiple myeloma.Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.New strategies in the treatment of multiple myeloma.Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.Minor clone provides a reservoir for relapse in multiple myeloma Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma.Gene expression profile alone is inadequate in predicting complete response in multiple myeloma.New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.A novel measure of chromosome instability can account for prognostic difference in multiple myeloma.Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma.Effectiveness of targeted therapy as monotherapy or combined therapy in patients with relapsed or refractory multiple myeloma: a systematic review and meta-analysis.RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway.Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma.High levels of circulating CD34+ cells at autologous stem cell collection are associated with favourable prognosis in multiple myeloma.Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study.Filtration markers as predictors of ESRD and mortality in Southwestern American Indians with type 2 diabetes.An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma.Clinical and prognostic significance of bone marrow abnormalities in the appendicular skeleton detected by low-dose whole-body multidetector computed tomography in patients with multiple myeloma.European perspective on multiple myeloma treatment strategies: update following recent congresses Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party.Adverse prognostic impact of bone marrow microvessel density in multiple myeloma Utilization of magnetic-activated cell sorting and high-density single nucleotide polymorphism microarrays improves diagnostic yield and prognostic value in clinical testing for patients with multiple myeloma and normal routine chromosome study Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation Clinically relevant measures of fit? A note of caution.Multiple Myeloma: Treatment is Getting Individualized Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long-term follow-up study Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma.

P2860

Q21133524-532E2F82-5766-47C0-BE8D-C45C0AF0C2A4 Q24197999-39A13ED5-C763-42D3-A89A-940FF244CCCE Q24202358-04C967C3-3B9D-4772-B253-26E2D5C9E708 Q26852892-7062F749-16DA-4444-BD10-87BA8A86F25B Q26996524-79B7108B-4AE5-49A1-B067-DCCD09ACFFDE Q27002668-A243F664-0466-4163-9CDD-20F370CF1091 Q28067148-DD1578BD-EB38-49DF-AEE6-9CBA3296BB13 Q30244061-72206A6A-A128-40F9-9CCE-D942B5544F9D Q33410213-64B63D40-99C5-4AD7-A22D-1F59A09EFE2D Q33573752-BA0CA0FB-4EB4-42E0-8E6E-BC3253C21271 Q33586505-589DF967-B4C2-4E24-A3BB-3F2BBEB84AEA Q33685400-BACE8A1E-2B8C-43A7-84C9-DCFAFDFCA8C6 Q33914824-229BD9E8-F0C8-47C0-9F7D-30E5A24EBB40 Q33956990-07691D51-C707-4444-9A82-F47DE9EB5A9C Q33958520-30EAE0D9-DAB4-48B6-BBE3-15D069699C78 Q34009070-A6E480EA-FA8F-4933-9C59-06CDD9097D46 Q34115051-FA784B96-708E-487C-B1CB-B5FC7B7FB662 Q34147170-78122DEB-F88E-4750-BB59-D76B785C42BA Q34173892-D624223B-FD1D-461B-9E57-3E8E148FCE40 Q34345502-6F7A132B-2603-4C29-8843-4C8F5F07068A Q34773850-C42992EB-5456-4B79-A16F-9304686DB3AF Q34805291-3C97C9AA-550C-4EF8-BB72-994D135A7C6C Q35097105-448CF114-F836-4D07-B64A-3D52D3178D88 Q35104606-06C04C23-E9DE-4397-9AF3-0D01190658E9 Q35187880-9E1E4172-2154-4A31-A0EF-EB58B232B10B Q35246395-9364CF0B-B222-4BB4-B45A-EAE39FE3EA9F Q35263009-2FF40567-9C88-47D4-8851-1A22488AF793 Q35778467-3AF805ED-1A4D-4A03-8138-22BB65A73ABA Q35797913-8E764723-DCEE-4F0C-AD69-7461896605F5 Q35868171-D92A4790-DB16-4C9E-B71B-211B0F6CB7AB Q35921897-ED2625A6-3857-44F8-A28E-243B910DBEC0 Q35989943-71D89D0F-6E71-423F-802B-47F7854FD6CA Q36000415-3B954702-986C-4022-BB02-DC9AA3B2D182 Q36083670-F25B8739-828B-4C23-80F4-84004B1C4C0B Q36193269-F6B67228-CB26-4877-B8D5-8E9860211E1B Q36279610-A4918B41-9DBF-4FAB-A840-79A0BFF44E7D Q36489222-D5EFC554-8108-4794-B74F-C86870743BC1 Q36522964-F0A83306-D89B-4408-ABF4-4A6E6319BD49 Q36524579-774660CA-2461-4A94-BD1B-062B54A30699 Q36526999-EFB0183B-BE1C-4331-8CB2-EC96FDA8EFE8

P2860

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

http://www.wikidata.org/entity/Q37835572

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 03 February 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Consensus recommendations for ...... ma Workshop Consensus Panel 2.

@en

Consensus recommendations for ...... ma Workshop Consensus Panel 2.

@nl

type

label

Consensus recommendations for ...... ma Workshop Consensus Panel 2.

@en

Consensus recommendations for ...... ma Workshop Consensus Panel 2.

@nl

prefLabel

Consensus recommendations for ...... ma Workshop Consensus Panel 2.

@en

Consensus recommendations for ...... ma Workshop Consensus Panel 2.

@nl

P1433

Q37835572-4D3CAB00-C23E-491A-9252-026904108D8B

P1476

Q37835572-7B6EF972-D630-4D87-BE1E-BA85EE2CCB11

P2093

Q37835572-06E811F7-6513-4A6F-9BD1-EE84BAFF6C53

Q37835572-39248577-8CA7-4188-A45E-4B077736DE1D

Q37835572-50741382-10CB-4F7F-BDC1-4C2209BDF279

Q37835572-651DB2C7-1961-4CF4-9B47-6A1AF4854A81

Q37835572-98141079-71DB-4A8E-BE6C-8CB9D4D3AC94

Q37835572-98851572-62CD-43AF-BBB0-69C5401C5F4E

Q37835572-B4A4D7EF-2BF1-422D-B6A7-93FBCCBA5BF7

Q37835572-BAA83346-6D5C-4098-AEF4-69BA3BA1B259

Q37835572-D2BAE1C1-37A2-4DF0-90AB-31D01622C663

Q37835572-FF3328EC-15F7-4CBC-A9F4-FC0EA95725E1

P2860

Q37835572-0478D01C-EAC3-44E6-8805-C2A1E9E1E10D

Q37835572-1405C401-2FC7-4F57-A408-02582B0DEE93

Q37835572-23E09D21-263C-4ADA-B116-4489FE1A9395

Q37835572-3511E51F-8E66-4300-BB65-475116FBF9D9

Q37835572-36381BEF-21AE-4972-9772-5775709B68D2

Q37835572-42779F92-A986-4B30-B625-2F55E490A8DF

Q37835572-49F3DBCA-F3FE-4067-BB7E-CF0BCDE46189

Q37835572-4D9B1845-2B1B-4B64-9041-9AC78D2673D3

Q37835572-549A723C-C80E-45DC-8F8A-CAF36B8D115D

Q37835572-66B8CE86-BCE2-457F-9169-A9005F0C71D0

P304

Q37835572-26C93737-324A-43FD-8D1B-36FC9ADA9559

P31

Q37835572-BA8CE31A-EF8C-437F-8B85-9DAC44C350CC

P356

Q37835572-28957A29-2C9F-4DB1-A815-757B65007A01

P407

Q37835572-6760F515-FAA0-4DB7-93D3-18191B9765FE

P433

Q37835572-CEA45640-B32D-4006-9AAD-7C73993FC47B

P478

Q37835572-8FC92B48-B90B-43CA-8868-42CD6EA2E89C

P50

Q37835572-185E02BA-5531-49FC-8A8E-C80CA1A31934

Q37835572-1D297DC2-4661-45A3-83F8-54E73D577244

Q37835572-2E4DEA74-B683-41E4-86E3-1923082E6E28

Q37835572-36983602-DA2C-4B7A-904A-378FBD59B351

Q37835572-6F1EABF2-7048-4A1D-9CE2-76C44FDB6B42

Q37835572-7CEEC697-4EA6-4971-87CA-CE95F6EB155E

Q37835572-9DEC5B63-7067-4CC6-8D98-F6364668B4F0

Q37835572-B8076ED6-33F2-4AD4-96FC-6CCFBABA23B8

Q37835572-C82D5886-029F-4C60-A323-CDCBA9123E63

Q37835572-D318E394-C51F-42AD-8606-F0BF6029151A

P577

Q37835572-16E481E8-5CAB-47AF-9CA6-B6DC58069927

P5875

Q37835572-3079F764-D508-444D-9D39-B4173110D1E0

P698

Q37835572-E74128E6-F291-4D49-BB91-0443416AD947

P921

Q37835572-8A81AEE5-AB60-4768-A165-7AF38BCD7936

P932

Q37835572-344B589E-E48C-4BDE-83B4-919187072149

P356

BLOOD-2010-10-300970

P1433

P1476

Consensus recommendations for ...... ma Workshop Consensus Panel 2.

@en

P2093

A Keith Stewart

http://www.w3.org/2001/XMLSchema#string

Brian Durie

http://www.w3.org/2001/XMLSchema#string

International Myeloma Workshop Consensus Panel 2

http://www.w3.org/2001/XMLSchema#string

Jean-Luc Harousseau

http://www.w3.org/2001/XMLSchema#string

John Crowley

http://www.w3.org/2001/XMLSchema#string

John Shaughnessy

http://www.w3.org/2001/XMLSchema#string

Nikhil C Munshi

http://www.w3.org/2001/XMLSchema#string

Orhan Sezer

http://www.w3.org/2001/XMLSchema#string

P Leif Bergsagel

http://www.w3.org/2001/XMLSchema#string

Sundar Jagannath

http://www.w3.org/2001/XMLSchema#string

P2860

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

Plasma cell leukaemia and other aggressive plasma cell malignancies.

Prognostic factors in multiple myeloma.

Primary plasma cell leukemia and autologous stem cell transplantation.

International staging system for multiple myeloma.

Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

Role of genetics in prognostication in myeloma.

Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone

F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.

P304

4696-4700

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-10-300970

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

Hervé Avet-Loiseau

Meletios A. Dimopoulos

Jesus San Miguel

S. Vincent Rajkumar

Kenneth C Anderson

Pieter Sonneveld

P577

2011-02-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49809260

http://www.w3.org/2001/XMLSchema#string

P698

21292777

http://www.w3.org/2001/XMLSchema#string

P921

P932

3293763

http://www.w3.org/2001/XMLSchema#string